February 2004

Growth Hormone Treatment for Idiopathic Short StatureImplications for Practice and Policy

Author Affiliations

Not Available


Copyright 2004 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.2004

Arch Pediatr Adolesc Med. 2004;158(2):108-110. doi:10.1001/archpedi.158.2.108

The July 2003 approval of biosynthetic growth hormone (GH) by the Food and Drug Administration (FDA) for treating children with idiopathic short stature1 has raised questions from physicians, parents, and the media about the appropriate use of this treatment and the effect of this decision on US children.2,3 This editorial reviews the implications of the new GH indication for pediatric practice and policy.

First Page Preview View Large
First page PDF preview
First page PDF preview